IKOULA
5.3.2020 14:02:14 CET | Business Wire | Press release
IKOULA – leader in dedicated servers, outsourcing and Cloud Computing – innovates by launching the first IPv6 & IPv4 micro server . By combining the Raspberry Pi 4 technology with IKOULA professional infrastructure and 24/7 support, the French hoster introduce a versatile dedicated server for less than €10 / month.
“When we created IKOULA in 1998, we were ahead of our time by anticipating the explosion of Web. Even today, it is important for us to anticipate the needs of our customers, by offering them innovative products,” explains Jules-Henri GAVETTI, CEO & co-founder of IKOULA. "By providing these two types of IP, we anticipate the shortage of IPv4, while allowing users to address all of their current services without any restriction."
Often wrongly perceived as a pure home server, the Raspberry Pi 4 hides its true nature. It can be a great tool for a professional usage when it is used in “Remote” mode, in a datacenter. By choosing to host their Raspberry remotely, users can benefit from the security system of a datacenter, a support team available at all times, but above all they can benefit from a high availability, a professional electrical network and an asynchronous 1Gbps bandwidth. In other words, this product is the perfect mix to host a website, develop some applications, back up all kind of data, or even create a VPN, or a set of Docker servers.
The lower power consumption is another advantage of this kind of micro server, compared to a conventional dedicated server. Opting for this product will truly reduce the ecological impact of your activities.
For more information, please click here .
About IKOULA
Pioneer of the French Cloud since 1998, IKOULA owns its own Datacenters in France (Reims and Laon), as well as two subsidiaries in Spain and the Netherlands. Because Human Being is part of its DNA, IKOULA maintains a close relationship with its customers, and puts at their disposal reactive teams of experts, available 24/7, able to advise them and accompany them in their activities. IKOULA's teams are multilingual, in order to meet the internationalization challenges of all its customers, spread over more than 60 countries on 4 continents.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200305005358/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Egon Zehnder Names Ayşe Güçlü Onur Global Human Resources Practice Leader2.9.2026 15:00:00 CEST | Press release
Egon Zehnder has appointed Ayşe Güçlü Onur as Global Leader of its Human Resources Practice. This appointment comes as companies and boards increasingly look to CHROs to help shape business strategy, lead transformation, build leadership pipelines, and navigate major shifts in culture and the workforce. "CHROs used to be evaluated by how well they supported the business. Today, the best drive it," said Onur. "Our role is to help CHROs move from a seat at the table to a hand in business growth. We help them connect leadership decisions, talent, and culture directly to elevated performance. That's the shift Egon Zehnder is built to guide with our leadership advisory services." Egon Zehnder’s Human Resources Practice partners with companies to discover, develop, and transform future-ready CHROs, helping them shape the future of the function. This includes executive search, leadership assessment and development, board effectiveness, culture, succession planning, organizational transformati
Safe Software to Increase Global Headcount by Over 15% as Demand for AI-Ready Data Grows2.9.2026 15:00:00 CEST | Press release
The FME creator is recruiting for more than 60 roles across the UK, US and Canada before the end of December, less than a year after crossing $100M in revenue Safe Software, the creator of FME, the only All-Data, Any-AI enterprise integration platform with true support for spatial data, today announced it is recruiting for more than 60 roles throughout the remainder of 2026. The hiring will take the company past 400 employees, increasing headcount by over 15%, with new positions across the United Kingdom, the United States and Canada. The expansion follows a year in which Safe crossed $100 million in annual revenue, growing close to 20 percent year over year and moving ahead of schedule on its target of $250 million by 2028. The company also grew its employee base by over 20% in the same period. "The incredible growth that we’ve seen over the last 30+ years at Safe has always been a testament to the great people behind what we do," said Don Murray, Co-Founder and CEO of Safe Software.
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Datato Boehringer Ingelheim2.9.2026 14:00:00 CEST | Press release
Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset. Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network. Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities supp
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience2.9.2026 14:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. The licensed VHH antibody molecule was generated from Biocytogen’s proprietary RenNano® platform. The RenNano® platform is designed to discover fully human VHH antibody molecules with favorable specificity, binding affinity, and developability, and can generate molecular building blocks for the design and development of VHH antibodies, bispecific/multispecific antibodies, antibody-drug conjugates, and other innovative modalities. Through this license, Qilu Pharmaceutical may advance the research and development o
Croma-Pharma Introduces Electronic Instructions for Use Across the saypha® Portfolio2.9.2026 13:37:00 CEST | Press release
Healthcare professionals in eligible markets can now access the Instructions for Use for the saypha® portfolio digitally by scanning a QR code on the product packaging Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation. Healthcare professionals can access the current approved Instructions for Use by scanning the QR code on the saypha® folding box. The eIFU platform provides direct digital access to the latest approved Instructions for Use. "Innovation extends beyond product development. It also includes how we provide healthcare professionals with access to essential product information," said Andreas Prinz, Chief Executive Officer of Croma-Pharma. "The introduction of electronic Instructio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom